JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

Odonate Therapeutics Inc

Chiusa

0

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

Massimo

Metriche Chiave

By Trading Economics

Odonate Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 feb 2026, 23:57 UTC

Discorsi di Mercato

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8 feb 2026, 23:47 UTC

Discorsi di Mercato

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8 feb 2026, 23:43 UTC

Discorsi di Mercato

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8 feb 2026, 23:34 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 feb 2026, 23:34 UTC

Discorsi di Mercato

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8 feb 2026, 23:26 UTC

Discorsi di Mercato

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8 feb 2026, 22:55 UTC

Utili

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8 feb 2026, 22:55 UTC

Utili

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8 feb 2026, 22:55 UTC

Utili

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8 feb 2026, 22:55 UTC

Utili

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8 feb 2026, 22:55 UTC

Utili

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8 feb 2026, 22:55 UTC

Utili

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8 feb 2026, 21:43 UTC

Discorsi di Mercato

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8 feb 2026, 21:16 UTC

Discorsi di Mercato

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8 feb 2026, 21:15 UTC

Discorsi di Mercato

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7 feb 2026, 09:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

7 feb 2026, 09:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

7 feb 2026, 05:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

7 feb 2026, 02:46 UTC

Acquisizioni, Fusioni, Takeovers

Big Money, High Anxiety -- Barrons.com

6 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 feb 2026, 21:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

6 feb 2026, 21:40 UTC

Acquisizioni, Fusioni, Takeovers

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 feb 2026, 21:22 UTC

Discorsi di Mercato

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 feb 2026, 21:17 UTC

Utili

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 21:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

6 feb 2026, 21:14 UTC

Acquisizioni, Fusioni, Takeovers

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 feb 2026, 21:13 UTC

Utili

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 feb 2026, 21:13 UTC

Utili

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 feb 2026, 21:04 UTC

Discorsi di Mercato

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 feb 2026, 20:34 UTC

Utili

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Odonate Therapeutics Inc Previsione

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

EBITDA

Utile operativo

$

Chi Siamo Odonate Therapeutics Inc

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
help-icon Live chat